Pipeline

Pipelines under development

The development of our pipelines is introduced here.​

SPP-005
Aminolevulinic acid hydrochloride

Photodynamic diagnosis to advanced gastric cancer with staging laparoscopy

Osaka University
(Provision to investigator-initiated trial)

Phase III

SPP-004
Combination of aminolevulinic acid hydrochloride and sodium ferrous citrate

Mitochondrial Disease

Saitama Medical University and National Center for Child Health and Development
(Provision to investigator-initiated trial)

Phase III

SPP-003
Combination of aminolevulinic acid hydrochloride and Sodium Ferrous Citrate

Renal function decline by cisplatin chemotherapy

Self-development

Phase II

Combination of aminolevulinic acid hydrochloride and Sodium Ferrous Citrate

Ischemia reperfusion injury

University of Oxford, University of Leicester, University of Birmingham & University of Cambridge
(Provision to investigator-initiated trial)

Under preparation

Combination of aminolevulinic acid hydrochloride and Sodium Ferrous Citrate

Brain tumor (interstitial photodynamic therapy)

University of Münster
(Provision to investigator-initiated trial)

Under preparation

Aminolevulinic acid hydrochloride

Cutaneous ulcer infected with methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant Pseudomonas aeruginosa

TBD

Under preparation

Aminolevulinic acid hydrochloride

Reinforcement of cancer radiotherapy

TBD

Under preparation

Aminolevulinic acid hydrochloride

photodynamic diagnosis of bladder cancer

TBD

Under preparation

SBI Phama's Pipeline

Adaptation level

Main developer

Phase

Sponsor initiated

Changing dosage of Alaglio for the bladder cancer PDD indication

In-house

SPP-005 Aminolevulinic acid hydrochloride
Phase III

Reinforcement of cancer radiotherapy

TBD

Aminolevulinic acid hydrochloride
under preparation

SBI ALAPharma group's Pipeline

Adaptation level

Main developer

Phase

Investigator initiated

Ischemia reperfusion injury

University of Oxford/  University of Leicester/  University of Birmingham/  University of Cambridge

Combination of aminolevulinic acid hydrochloride and Sodium Ferrous Citrate
Phase II

Sponsor initiated

Photodynamic diagnosis of breast cancer

In-house

 

Aminolevulinic acid hydrochloride
Phase III

Sponsor initiated

Additional indication of Gleolan for the photodynamic diagnosis

In-house

Aminolevulinic acid hydrochloride
Phase III

Investigator initiated

Interstitial photodynamic therapy for recurrence of malignant glioma

University Hospital Münster

 

Aminolevulinic acid hydrochloride
Phase IIb

Sponsor initiated

Interstitial photodynamic therapy for primary malignant glioma

In-house

Aminolevulinic acid hydrochloride
Phase I/II

SBI Phama's Pipeline

Changing dosage of Alaglio for the bladder cancer PDD indication
Phase III
Reinforcement of cancer radiotherapy
Under preparation

SBI ALAPharma group's Pipeline

Ischemia reperfusion injury
Phase II
Photodynamic diagnosis of breast cancer
Phase III
Additional indication of Gleolan for the photodynamic diagnosis
Phase III
Interstitial photodynamic therapy for recurrence of malignant glioma
Phase IIb
Interstitial photodynamic therapy for primary malignant glioma
Phase I/II
Mechanical Translations by Google »